Alliancebernstein L.P. maintained its position in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) during the first quarter, Holdings Channel reports. The firm owned 22,300 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alliancebernstein L.P.’s holdings in OncoMed Pharmaceuticals were worth $205,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of OMED. American International Group Inc. increased its position in OncoMed Pharmaceuticals by 9.0% in the first quarter. American International Group Inc. now owns 10,977 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 905 shares during the period. SG Americas Securities LLC increased its position in OncoMed Pharmaceuticals by 312.7% in the first quarter. SG Americas Securities LLC now owns 58,626 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 44,419 shares during the period. Trexquant Investment LP purchased a new position in OncoMed Pharmaceuticals during the first quarter worth approximately $372,000. Ameriprise Financial Inc. purchased a new position in OncoMed Pharmaceuticals during the first quarter worth approximately $6,266,000. Finally, Swiss National Bank increased its position in OncoMed Pharmaceuticals by 22.1% in the first quarter. Swiss National Bank now owns 33,200 shares of the biopharmaceutical company’s stock worth $306,000 after buying an additional 6,000 shares during the period. Institutional investors and hedge funds own 44.18% of the company’s stock.

Shares of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) traded down 1.86% during trading on Friday, reaching $4.23. 46,163 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $3.60 and a 200-day moving average price of $5.57. OncoMed Pharmaceuticals, Inc. has a 52-week low of $2.91 and a 52-week high of $12.58. The company’s market capitalization is $159.17 million.

OncoMed Pharmaceuticals (NASDAQ:OMED) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.10. The business had revenue of $6.20 million during the quarter, compared to the consensus estimate of $6.08 million. The business’s revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.91) EPS. On average, equities analysts forecast that OncoMed Pharmaceuticals, Inc. will post ($1.85) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/18/oncomed-pharmaceuticals-inc-omed-stake-held-by-alliancebernstein-l-p.html.

A number of research firms recently commented on OMED. Piper Jaffray Companies set a $5.00 price target on OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, July 10th. Jefferies Group LLC reiterated a “buy” rating and issued a $5.00 price target on shares of OncoMed Pharmaceuticals in a research note on Sunday, July 9th. ValuEngine downgraded OncoMed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. HC Wainwright decreased their price target on OncoMed Pharmaceuticals from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, May 15th. Finally, Cantor Fitzgerald set a $6.00 price target on OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

In other OncoMed Pharmaceuticals news, Director Perry A. Karsen bought 10,000 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were acquired at an average price of $3.46 per share, with a total value of $34,600.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $34,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jonathan D. Root sold 13,880 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $3.71, for a total transaction of $51,494.80. Following the completion of the sale, the director now directly owns 121,020 shares in the company, valued at approximately $448,984.20. The disclosure for this sale can be found here. In the last three months, insiders purchased 64,614 shares of company stock worth $222,249. 32.80% of the stock is currently owned by insiders.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Want to see what other hedge funds are holding OMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED).

Institutional Ownership by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.